Therapeutics News

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

Prescribers have expressed an overall positive opinion toward the off-label use of low-dose oral minoxidil for the treatment of androgenetic alopecia, though opinions varied based on years of experience, according to a study.

SAN DIEGO — Basal cell carcinoma treatment with jet injection of photodynamic therapy was well tolerated by patients in a pilot study, according to a poster presentation at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In this Healio video perspective here at the American Academy of Dermatology, Brett King, MD, PhD, FAAD, discusses how new Janus kinase inhibitors have changed the paradigm of alopecia areata treatment.

SAN DIEGO — In this video perspective, Healio Dermatology Chief Medical Editor Joel M. Gelfand, MD, MSCE, discusses highlights from the LITE study on home vs. office-based phototherapy for plaque or guttate psoriasis.

SAN DIEGO — In this video perspective, Menas Kizoulis, senior director of global scientific engagement at Kenvue, discusses the company’s latest research presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In a real-world setting, treatment with home-based phototherapy was noninferior to office phototherapy for people with plaque or guttate psoriasis, with both options safe and efficacious, according to a speaker here.

SAN DIEGO — The Skin of Color Society has awarded innovation grants to two finalists at the 20th Annual Skin of Color Society Scientific Symposium.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.

Using the efficiency frontier approach to negotiate prices for plaque psoriasis biologics may lead to substantial price reductions that better align with clinical benefits in the U.S., according to a study.